Unknown Primary Tumors: An Example of Accelerated (Type 2) Tumor Progression
The acquisition of the malignant phenotype (invasiveness and metastasis) by tumor cells has been attributed to tumor progression, a term used by Foulds to describe the acquisition of permanent irreversible changes in a neoplasm1. Progression in turn has generally been presumed to result from “genetic instability” that results in the emergence of neoplastic cells that have lost control of the mechanisms governing or regulating gene expression2,3. From these ideas evolved the proposal that tumor progression is generally unidirectional, since genetic or genomic changes favoring malignant cells with some form of a presumed growth advantage generally come to dominate tumor growth. The advantages acquired by these cells were hypothesized to be due to an increasing rate of genomic instability that accompanied the increasingly malignant phenotype4,5. Thus, it is believed that only cells with an increased rate of genomic instability become malignant (metastatic). In short the transformation of normal cells into tumor cells is thought to be accompanied by the destabilization of the genome, leading to tumor heterogeneity which in turn accompanies tumor progression to a malignant phenotype. One difficulty with this paradigm is that we have only a minimal understanding of the events responsible for the transformation of a normal to a malignant cell. It has therefore been accepted a priori that any analysis of tumor initiation, promotion and progression accept this gap in knowledge and proceed from there.
KeywordsTumor Progression Genomic Instability Genetic Instability Malignant Phenotype Genomic Change
Unable to display preview. Download preview PDF.
- 6.B. C. Morson and I. M. P. Dawson, “Gastrointestinal Pathology,” 2nd ed., Blackwell Scientific, London (1979).Google Scholar
- 8.Y. H. Pilch, Malignant Melanoma, in: “Surgical Oncology”, Y. H. Pilch, McGraw Hill, New York (1984).Google Scholar
- 15.P. Frost, W. S. Kendal, B. Hunt, and M. Ellis, The prevalence of ouabain resistant variants after mutagen treatment: failure to correlate the frequency of variant expression with the metastatic phenotype, Invasion and Metastasis 8:73–86 (1988).Google Scholar
- 16.T. C. Everson and W. H. Cole, “Spontaneous Regression of Cancer,” Saunders Pub., Philadelphia (1966).Google Scholar
- 17.P. Frost, W. S. Kendal, and R. S. Kerbel, The limits of tumor heterogeneity, in: “Neo-adjuvant Chemotherapy,” Colloque INSERM/John Libbey Eurotext Ltd. 137-57-60 (1986).Google Scholar
- 18.J. L. Abbruzzese, M. N. Raber, and P. Frost, An effective strategy for the evaluation of unknown primary tumors, Cancer Bulletin (1988).Google Scholar
- 19.C. Bell and P. Frost, Characterization of two cell lines derived from human metastatic adenocarcinomas of unknown primary origin (UPT), Proc AACR 29:28 (1988).Google Scholar